nach oben

Clinical Oral Investigations

Erschienen in:

03.01.2018 | Review

MicroRNAs as effective surrogate biomarkers for early diagnosis of oral cancer

verfasst von: Min Cao, Lijuan Zheng, Jianzhou Liu, Thomas Dobleman, Shen Hu, Vay Liang W. Go, Ge Gao, Gary Guishan Xiao

Erschienen in: Clinical Oral Investigations | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Oral squamous cell carcinomas (OC) are life-threatening diseases emerging as major international health concerns.

Objective

Development of an efficient clinical strategy for early diagnosis of the disease is a key for reducing the death rate. Biomarkers are proven to be an effective approach for clinical diagnosis of cancer. Although mechanisms underlying regulation of oral malignancy are still unclear, microRNAs (miRNAs) as a group of small non-coded RNAs may be developed as the effective biomarkers used for early detection of oral cancer.

Methods

A literature search was conducted using the databases of PubMed, Web of Science, and the Cochrane Library. The following search terms were used: miRNAs and oral cancer or oral carcinoma. A critical appraisal of the included studies was performed with upregulated miRNAs and downregulated miRNAs in oral cancer.

Results

In this review, we summarize the research progress made in miRNAs for diagnosis of oral cancer. The involvement of miRNAs identified in signal transduction pathways in OC, including Ras/MAPK signaling, PI3K/AKT signaling, JAK/STAT signaling, Wnt/β-catenin signaling, Notch signaling, and TGF-β/SMAD signaling pathway.

Conclusions

A number of studies demonstrated that miRNAs may be developed as an ideal set of biomarkers used for early diagnosis and prognosis of cancers because of the stability in human peripheral blood and body fluids and availability of non-invasive approaches being developed for clinical utility. Clinical relevance: These findings suggest that miRNAs as biomarkers may be useful for diagnosis of OC.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108. https://doi.org/10.3322/caac.21262 PubMedCrossRef

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30. https://doi.org/10.3322/caac.21332 PubMedCrossRef

Van Dijk BAC, Brands MT, Geurts SME et al (2016) Trends in oral cavity cancer incidence, mortality, survival and treatment in the Netherlands. Int J Cancer 139(3):574–583. https://doi.org/10.1002/ijc.30107 PubMedCrossRef

Derbi HA, Kruger E, Tennant M (2016) Incidence of oral cancer in Western Australia (1982-2009): trends and regional variations. Asian Pac J Clin Oncol 12(2):e305–e310. https://doi.org/10.1111/ajco.12205 CrossRef

Zhang J, Gao F, Yang AK et al (2016) Epidemiologic characteristics of oral cancer: sngle-center analysis of 4097 patients from the Sun Yat-Sen University Cancer Center. Chin J Cancer 35:190–195

Johnson NW, Jayasekara P, Amarasinghe AAHK (2011) Squamous cell carcinoma and precursor lesions of the oral cavity: epidemiology and aetiology. Periodontol 57(1):19–37. https://doi.org/10.1111/j.1600-0757.2011.00401.x CrossRef

Enwonwu CO, Sanders C (2001) Nutrition: impact on oral and systemic health. Compend Contin Educ Dent 22:12–18PubMed

Blot WJ, Mclaughlin JK, Winn DM et al (1988) Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 48(11):3282–3287PubMed

Chawla JPS, Iyer N, Soodan KS, Sharma A, Khurana SK, Priyadarshni P (2015) Role of miRNA in cancer diagnosis, prognosis, therapy and regulation of its expression by Epstein–Barr virus and human papillomaviruses: with special reference to oral cancer. Oral Oncol 51(8):731–737. https://doi.org/10.1016/j.oraloncology.2015.05.008 PubMedCrossRef

10.

Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS, Gillison ML (2011) Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29(32):4294–4301. https://doi.org/10.1200/JCO.2011.36.4596 PubMedPubMedCentralCrossRef

11.

Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, Rosenberg PS, Bray F, Gillison ML (2013) Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 31(36):4550–4559. https://doi.org/10.1200/JCO.2013.50.3870 PubMedPubMedCentralCrossRef

12.

Heck JE, Berthiller J, Vaccarella S, Winn DM, Smith EM, Shan'gina O, Schwartz SM, Purdue MP, Pilarska A, Eluf-Neto J, Menezes A, McClean MD, Matos E, Koifman S, Kelsey KT, Herrero R, Hayes RB, Franceschi S, Wünsch-Filho V, Fernández L, Daudt AW, Curado MP, Chen C, Castellsagué X, Ferro G, Brennan P, Boffetta P, Hashibe M (2010) Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol 39(1):166–181. https://doi.org/10.1093/ije/dyp350 PubMedCrossRef

13.

Guha N, Warnakulasuriya S, Vlaanderen J, Straif K (2014) Betel quid chewing and the risk of oral and oropharyngeal cancers: a meta-analysis with implications for cancer control. Int J Cancer 135(6):1433–1443. https://doi.org/10.1002/ijc.28643 PubMedCrossRef

14.

Rao SVK, Mejia G, Roberts-Thomson K, Logan R (2013) Epidemiology of oral cancer in Asia in the past decade—an update (2000-2012). Asian Pac J Cancer Prev 14(10):5567–5577. https://doi.org/10.7314/APJCP.2013.14.10.5567 CrossRef

15.

Tirelli G, Zacchigna S, Biasotto M, Piovesana M (2016) Open questions and novel concepts in oral cancer surgery. Eur Arch Otorhinolaryngol 273(8):1975–1985. https://doi.org/10.1007/s00405-015-3655-0 PubMedCrossRef

16.

Shang HG, HL Y, Ma XN et al (2016) Multidrug resistance and tumor-initiating capacity of oral cancer stem cells. J Buon 21(2):461–465PubMed

17.

Pepe MS, Feng ZD, Thompson ML et al (2001) Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93(14):1054–1061. https://doi.org/10.1093/jnci/93.14.1054 PubMedCrossRef

18.

Biankin AV, Piantadosi S, Hollingsworth SJ (2015) Patient-centric trials for therapeutic development in precision oncology. Nature 526(7573):361–370. https://doi.org/10.1038/nature15819 PubMedCrossRef

19.

Polanska H, Raudenska M, Gumulec J, Sztalmachova M, Adam V, Kizek R, Masarik M (2014) Clinical significance of head and neck squamous cell cancer biomarkers. Oral Oncol 50(3):168–177. https://doi.org/10.1016/j.oraloncology.2013.12.008 PubMedCrossRef

20.

Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105(30):10513–10518. https://doi.org/10.1073/pnas.0804549105 PubMedPubMedCentralCrossRef

21.

Chen X, Ba Y, Ma LJ et al (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18(10):997–1006. https://doi.org/10.1038/cr.2008.282 PubMedCrossRef

22.

Courthod G, Franco P, Palermo L, Pisconti S, Numico G (2014) The role of microRNA in head and neck cancer: current knowledge and perspectives. Molecules 19(5):5704–5716. https://doi.org/10.3390/molecules19055704 PubMedCrossRef

23.

Di LG, Garofalo M, Croce CM (2014) MicroRNAs in cancer. Annu Rev Pathol 9:287–314CrossRef

24.

Fabbri M (2013) MicroRNAs and cancer: towards a personalized medicine. Curr Mol Med 13(5):751–756. https://doi.org/10.2174/1566524011313050006 PubMedCrossRef

25.

Gomes CC, Gomez RS (2008) MicroRNA and oral cancer: future perspectives. Oral Oncol 44(10):910–914. https://doi.org/10.1016/j.oraloncology.2008.01.002 PubMedCrossRef

26.

Ries J, Vairaktaris E, Kintopp R et al (2014) Alterations in miRNA expression patterns in whole blood of OSCC patients. In Vivo 28:851–862PubMed

27.

Cui J, Li DL, Zhang WM et al (2014) Bioinformatics analyses combined microarray identify the deregulated microRNAs in oral cancer. Oncol Lett 8(1):218–222. https://doi.org/10.3892/ol.2014.2070 PubMedPubMedCentralCrossRef

28.

Mirghani H, Ugolin N, Ory C, Goislard M, Lefèvre M, Baulande S, Hofman P, Guily JLS, Chevillard S, Lacave R (2016) Comparative analysis of micro-RNAs in human papillomavirus-positive versus -negative oropharyngeal cancers. Head Neck 38(11):1634–1642. https://doi.org/10.1002/hed.24487 PubMedCrossRef

29.

Lajer CB, Nielsen FC, Friis-Hansen L, Norrild B, Borup R, Garnæs E, Rossing M, Specht L, Therkildsen MH, Nauntofte B, Dabelsteen S, von Buchwald C (2011) Different miRNA signatures of oral and pharyngeal squamous cell carcinomas: a prospective translational study. Br J Cancer 104(5):830–840. https://doi.org/10.1038/bjc.2011.29 PubMedPubMedCentralCrossRef

30.

Korvala J, Jee K, Porkola E, Almangush A, Mosakhani N, Bitu C, Cervigne NK, Zandonadi FS, Meirelles GV, Leme AFP, Coletta RD, Leivo I, Salo T (2017) MicroRNA and protein profiles in invasive versus non-invasive oral tongue squamous cell carcinoma cells in vitro. Exp Cell Res 350(1):9–18. https://doi.org/10.1016/j.yexcr.2016.10.015 PubMedCrossRef

31.

Scapoli L, Palmieri A, Lo Muzio L et al (2010) MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int J Immunopathol Pharmacol 23(4):1229–1234. https://doi.org/10.1177/039463201002300427 PubMedCrossRef

32.

Manikandan M, Rao AKDM, Arunkumar G et al (2016) Oral squamous cell carcinoma: microRNA expression profiling and integrative analyses for elucidation of tumourigenesis mechanism. Mol Cancer 15(1):28. https://doi.org/10.1186/s12943-016-0512-8 PubMedPubMedCentralCrossRef

33.

Yang Y, Li YX, Yang X et al (2013) Progress risk assessment of oral premalignant lesions with saliva miRNA analysis. BMC Cancer 13(1):129. https://doi.org/10.1186/1471-2407-13-129 PubMedPubMedCentralCrossRef

34.

Wang JH, Wang W, Li JC et al (2017) miR182 activates the Ras-MEK-ERK pathway in human oral cavity squamous cell carcinoma by suppressing RASA1 and SPRED1. Oncol Targets Ther 10:667–679. https://doi.org/10.2147/OTT.S121864 CrossRef

35.

WC L, Kao SY, Yang CC et al (2014) EGF up-regulates miR-31 through the C/EBP beta signal cascade in oral carcinoma. PLoS One 9:e108049CrossRef

36.

Patel S, Rawal R (2016) Role of miRNA dynamics and cytokine profile in governing CD44v6/Nanog/PTEN axis in oral cancer: modulating the master regulators. Tumour Biol 37(11):14565–14575. https://doi.org/10.1007/s13277-016-5289-2 PubMedCrossRef

37.

Zhou X, Ren Y, Liu AQ et al (2014) STAT3 inhibitor WP1066 attenuates miRNA-21 to suppress human oral squamous cell carcinoma growth in vitro and in vivo. Oncol Rep 31(5):2173–2180. https://doi.org/10.3892/or.2014.3114 PubMedCrossRef

38.

Coutinho-Camillo CM, Lourengo SV, Nishimoto IN et al (2015) Expression of apoptosis-regulating miRNAs and target mRNAs in oral squamous cell carcinoma. Cancer Genet 208(7-8):382–389. https://doi.org/10.1016/j.cancergen.2015.04.004 PubMedCrossRef

39.

Peng HY, Jiang SS, Hsiao JR, Hsiao M, Hsu YM, Wu GH, Chang WM, Chang JY, Jin SLC, Shiah SG (2016) IL-8 induces miR-424-5p expression and modulates SOCS2/STAT5 signaling pathway in oral squamous cell carcinoma. Mol Oncol 10(6):895–909. https://doi.org/10.1016/j.molonc.2016.03.001 PubMedPubMedCentralCrossRef

40.

Baba O, Hasegawa S, Nagai H et al (2013) MicroRNA-155-5p is associated with oral squamous cell carcinoma metastasis and poor prognosis. J Oral Pathol Med 45:248–255CrossRef

41.

Mitra S, Mukherjee N, Das S et al (2014) Anomalous altered expressions of downstream gene-targets in TP53-miRNA pathways in head and neck cancer. Sci Rep 4:6280PubMedPubMedCentralCrossRef

42.

Ricieri Brito JA, Gomes CC, Santos Pimenta FJ et al (2010) Reduced expression of mir15a in the blood of patients with oral squamous cell carcinoma is associated with tumor staging. Exp Ther Med 1(1):217–221. https://doi.org/10.3892/etm_00000035 PubMedPubMedCentralCrossRef

43.

Liu ZM, Diep C, Mao TT et al (2015) MicroRNA-92b promotes tumor growth and activation of NF-kappa B signaling via regulation of NLK in oral squamous cell carcinoma. Oncol Rep 34(6):2961–2968. https://doi.org/10.3892/or.2015.4323 PubMedCrossRef

44.

Tachibana H, Sho R, Takeda Y, Zhang X, Yoshida Y, Narimatsu H, Otani K, Ishikawa S, Fukao A, Asao H, Iino M (2016) Circulating miR-223 in oral cancer: its potential as a novel diagnostic biomarker and therapeutic target. PLoS One 11(7):e0159693. https://doi.org/10.1371/journal.pone.0159693 PubMedPubMedCentralCrossRef

45.

Cheng CM, Shiah SG, Huang CC, Hsiao JR, Chang JY (2016) Up-regulation of miR-455-5p by the TGF-β-SMAD signalling axis promotes the proliferation of oral squamous cancer cells by targeting UBE2B. J Pathol 240(1):38–49. https://doi.org/10.1002/path.4752 PubMedCrossRef

46.

Chen YF, Yang CC, Kao SY, Liu CJ, Lin SC, Chang KW (2016) MicroRNA-211 enhances the oncogenicity of carcinogen-induced oral carcinoma by repressing TCF12 and increasing antioxidant activity. Cancer Res 76(16):4872–4886. https://doi.org/10.1158/0008-5472.CAN-15-1664 PubMedCrossRef

47.

Shin KH, Bae SD, Hong HS, Kim RH, Kang MK, Park NH (2011) miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras. Biochem Biophys Res Commun 404(4):896–902. https://doi.org/10.1016/j.bbrc.2010.12.055 PubMedCrossRef

48.

Nakanishi H, Taccioli C, Palatini J, Fernandez-Cymering C, Cui R, Kim T, Volinia S, Croce CM (2014) Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway. Oncogene 33(6):702–712. https://doi.org/10.1038/onc.2013.13 PubMedCrossRef

49.

Christensen BC, Moyer BJ, Avissar M, Ouellet LG, Plaza SL, McClean MD, Marsit CJ, Kelsey KT (2009) A let-7 microRNA-binding site polymorphism in the KRAS 3′ UTR is associated with reduced survival in oral cancers. Carcinogenesis 30(6):1003–1007. https://doi.org/10.1093/carcin/bgp099 PubMedPubMedCentralCrossRef

50.

Yen YC, Shiah SG, Chu HC, Hsu YM, Hsiao JR, Chang JY, Hung WC, Liao CT, Cheng AJ, Lu YC, Chen YW (2014) Reciprocal regulation of MicroRNA-99a and insulin-like growth factor 1 receptor signaling in oral squamous cell carcinoma cells. Mol Cancer 13(1):6. https://doi.org/10.1186/1476-4598-13-6 PubMedPubMedCentralCrossRef

51.

Manikandan M, Deva MR, Arunagiri K et al (2015) Down regulation of miR-34a and miR-143 may indirectly inhibit p53 in oral squamous cell carcinoma: a pilot study. Asian Pac J Cancer Prev 16(17):7619–7625. https://doi.org/10.7314/APJCP.2015.16.17.7619 PubMedCrossRef

52.

Endo H, Muramatsu T, Furuta M, Uzawa N, Pimkhaokham A, Amagasa T, Inazawa J, Kozaki K (2013) Potential of tumor-suppressive miR-596 targeting LGALS3BP as a therapeutic agent in oral cancer. Carcinogenesis 34(3):560–569. https://doi.org/10.1093/carcin/bgs376 PubMedCrossRef

53.

Yang XL, Wu HJ, Ling TY (2014) Suppressive effect of microRNA-126 on oral squamous cell carcinoma in vitro. Mol Med Re 10(1):125–130. https://doi.org/10.3892/mmr.2014.2171 CrossRef

54.

Zhang YQ, Liu WL, Wang HL et al (2017) miRNA-126b regulated apoptosis of the human tongue carcinoma cell line Tca8113-P60 via P38 signaling pathway. Int J Clin Exp Med 10:2654–2659

55.

Minor J, Wang XT, Zhang F et al (2012) Methylation of microRNA-9 is a specific and sensitive biomarker for oral and oropharyngeal squamous cell carcinomas. Oral Oncol 48(1):73–78. https://doi.org/10.1016/j.oraloncology.2011.11.006 PubMedCrossRef

56.

Yu T, Liu K, Wu Y, Fan J, Chen J, Li C, Yang Q, Wang Z (2014) MicroRNA-9 inhibits the proliferation of oral squamous cell carcinoma cells by suppressing expression of CXCR4 via the Wnt/beta-catenin signaling pathway. Oncogene 33(42):5017–5027. https://doi.org/10.1038/onc.2013.448 PubMedCrossRef

57.

Ren YZ, Zhu HG, Chi CY et al (2015) MiRNA-139 regulates oral cancer Tca8113 cells apoptosis through Akt signaling pathway. Int J Clin Exp Pathol 8(5):4588–4594PubMedPubMedCentral

58.

Duz MB, Karatas OF, Guzel E et al (2016) Identification of miR-139-5p as a saliva biomarker for tongue squamous cell carcinoma: a pilot study. Cell Oncol 39(2):187–193. https://doi.org/10.1007/s13402-015-0259-z CrossRef

59.

Uesugi A, Kozaki K, Tsuruta T et al (2011) The tumor suppressive MicroRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res 71(17):5765–5778. https://doi.org/10.1158/0008-5472.CAN-11-0368 PubMedCrossRef

60.

Lee SA, Kim JS, Park SY, Kim HJ, Yu SK, Kim CS, Chun HS, Kim J, Park JT, Go D, Kim DK (2015) miR-203 downregulates Yes-1 and suppresses oncogenic activity in human oral cancer cells. J Biosci Bioeng 120(4):351–358. https://doi.org/10.1016/j.jbiosc.2015.02.002 PubMedCrossRef

61.

Shiah SG, Hsiao JR, Chang WM, Chen YW, Jin YT, Wong TY, Huang JS, Tsai ST, Hsu YM, Chou ST, Yen YC, Jiang SS, Shieh YS, Chang IS, Hsiao M, Chang JY (2014) Downregulated miR329 and miR410 promote the proliferation and invasion of oral squamous cell carcinoma by targeting Wnt-7b. Cancer Res 74(24):7560–7572. https://doi.org/10.1158/0008-5472.CAN-14-0978 PubMedCrossRef

62.

Kim JS, Park SY, Lee SA, Park MG, Yu SK, Lee MH, Park MR, Kim SG, Oh JS, Lee SY, Kim CS, Kim HJ, Chun HS, Kim JS, Moon SM, Kim DK (2014) MicroRNA-205 suppresses the oral carcinoma oncogenic activity via down-regulation of Axin-2 in KB human oral cancer cell. Mol Cell Biochem 387(1-2):71–79. https://doi.org/10.1007/s11010-013-1872-7 PubMedCrossRef

63.

Kim JS, Yu SK, Lee MH, Park MG, Park E, Kim SG, Lee SY, Kim CS, Kim HJ, Chun HS, Chun SW, Kim DK (2013) MicroRNA-205 directly regulates the tumor suppressor, interleukin-24, in human KB oral cancer cells. Mol Cells 35(1):17–24. https://doi.org/10.1007/s10059-013-2154-7 PubMedCrossRef

64.

Chang YC, Jan CI, Peng CY, Lai YC, Hu FW, Yu CC (2015) Activation of microRNA-494-targeting Bmi1 and ADAM10 by silibinin ablates cancer stemness and predicts favourable prognostic value in head and neck squamous cell carcinomas. Oncotarget 6(27):24002–24016. https://doi.org/10.18632/oncotarget.4365 PubMedPubMedCentral

65.

Weng JH, CC Y, Lee YC et al (2016) miR-494-3p induces cellular senescence and enhances radiosensitivity in human oral squamous carcinoma cells. Int J Mol Sci 17(7):1092. https://doi.org/10.3390/ijms17071092 PubMedCentralCrossRef

66.

Kai Y, Peng W, Ling W, Jiebing H, Zhuan B (2014) Reciprocal effects between microRNA-140-5p and ADAM10 suppress migration and invasion of human tongue cancer cells. Biochem Biophys Res Commun 448(3):308–314. https://doi.org/10.1016/j.bbrc.2014.02.032 PubMedCrossRef

67.

Piao LZ, Zhang MC, Datta J et al (2012) Lipid-based nanoparticle delivery of pre-miR-107 inhibits the tumorigenicity of head and neck squamous cell carcinoma. Mol Ther 20(6):1261–1269. https://doi.org/10.1038/mt.2012.67 PubMedPubMedCentralCrossRef

68.

Kikkawa N, Kinoshita T, Nohata N et al (2014) microRNA-504 inhibits cancer cell proliferation via targeting CDK6 in hypopharyngeal squamous cell carcinoma. Int J Oncol 44(6):2085–2092. https://doi.org/10.3892/ijo.2014.2349 PubMedCrossRef

69.

Yang MH, Lin BR, Chang CH, Chen ST, Lin SK, Kuo MYP, Jeng YM, Kuo ML, Chang CC (2012) Connective tissue growth factor modulates oral squamous cell carcinoma invasion by activating a miR-504/FOXP1 signalling. Oncogene 31(19):2401–2411. https://doi.org/10.1038/onc.2011.423 PubMedCrossRef

70.

Kozaki KI, Imoto I, Mogi S et al (2008) Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 68(7):2094–2105. https://doi.org/10.1158/0008-5472.CAN-07-5194 PubMedCrossRef

71.

Jia LF, Huang YP, Zheng YF et al (2015) miR-375 inhibits cell growth and correlates with clinical outcomes in tongue squamous cell carcinoma. Oncol Rep 33(4):2061–2071. https://doi.org/10.3892/or.2015.3759 PubMedCrossRef

72.

He K, Tong DD, Zhang S et al (2015) miRNA-99b-3p functions as a potential tumor suppressor by targeting glycogen synthase kinase-3 beta in oral squamous cell carcinoma Tca-8113 cells. Int J Oncol 47(4):1528–1536. https://doi.org/10.3892/ijo.2015.3135 PubMedCrossRef

73.

Tiwari A, Shivananda S, Gopinath KS, Kumar A (2014) MicroRNA-125a reduces proliferation and invasion of oral squamous cell carcinoma cells by targeting estrogen-related receptor alpha: implications for cancer therapeutics. J Biol Chem 289(46):32276–32290. https://doi.org/10.1074/jbc.M114.584136 PubMedPubMedCentralCrossRef

74.

Sun L, Yao Y, Liu B, Lin Z, Lin L, Yang M, Zhang W, Chen W, Pan C, Liu Q, Song E, Li J (2012) MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene 31(4):432–445. https://doi.org/10.1038/onc.2011.263 PubMedCrossRef

75.

BL W, Lei DL, Wang L et al (2016) MiRNA-101 inhibits oral squamous-cell carcinoma growth and metastasis by targeting zinc finger E-box binding homeobox 1. Am J Cancer Res 6:1396–1407

76.

Lin ZY, Sun LJ, Chen WL et al (2014) miR-639 regulates transforming growth factor beta-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting FOXC1. Cancer Sci 105(10):1288–1298. https://doi.org/10.1111/cas.12499 PubMedPubMedCentralCrossRef

77.

Murugan AK, Munirajan AK, Tsuchida N (2012) Ras oncogenes in oral cancer: the past 20 years. Oral Oncol 48(5):383–392. https://doi.org/10.1016/j.oraloncology.2011.12.006 PubMedCrossRef

78.

Santarpia L, Lippman SM, El-Naggar AK (2012) Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets 16(1):103–119. https://doi.org/10.1517/14728222.2011.645805 PubMedPubMedCentralCrossRef

79.

Murugan AK, Munirajan AK, Alzahrani AS (2016) MicroRNAs: modulators of the Ras oncogenes in oral cancer. J Cell Physiol 231(7):1424–1431. https://doi.org/10.1002/jcp.25269 PubMedCrossRef

80.

Shaw RJ, Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441(7092):424–430. https://doi.org/10.1038/nature04869 PubMedCrossRef

81.

Jia CY, Li HH, Zhu XC, Dong YW, Fu D, Zhao QL, Wu W, Wu XZ (2011) MiR-223 suppresses cell proliferation by targeting IGF-1R. PLoS One 6(11):e27008. https://doi.org/10.1371/journal.pone.0027008 PubMedPubMedCentralCrossRef

82.

Culig Z (2013) Interleukin-6 as a therapy target in oral squamous carcinoma. Expert Opin Ther Targets 17(1):53–59. https://doi.org/10.1517/14728222.2013.733368 PubMedCrossRef

83.

Yu H, Lee H, Herrmann A, Buettner R, Jove R (2014) Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 14(11):736–746. https://doi.org/10.1038/nrc3818 PubMedCrossRef

84.

Clevers H, Nusse R (2012) Wnt/beta-catenin signaling and disease. Cell 149(6):1192–1205. https://doi.org/10.1016/j.cell.2012.05.012 PubMedCrossRef

85.

Chaw SY, Majeed AA, Dalley AJ et al (2012) Epithelial to mesenchymal transition (EMT) biomarkers—E-cadherin, beta-catenin, APC and vimentin—in oral squamous cell carcinogenesis and transformation. Oral Oncol 48(10):997–1006. https://doi.org/10.1016/j.oraloncology.2012.05.011 PubMedCrossRef

86.

Wang ZW, Li YW, Kong DJ et al (2010) Cross-talk between miRNA and Notch signaling pathways in tumor development and progression. Cancer Lett 292(2):141–148. https://doi.org/10.1016/j.canlet.2009.11.012 PubMedCrossRef

87.

Hijioka H, Setoguchi T, Miyawaki A, Gao H, Ishida T, Komiya S, Nakamura N (2010) Upregulation of Notch pathway molecules in oral squamous cell carcinoma. Int J Oncol 36(4):817–822PubMed

88.

Yuan X, Wu H, HX X et al (2015) Notch signaling: an emerging therapeutic target for cancer treatment. Cancer Lett 369(1):20–27. https://doi.org/10.1016/j.canlet.2015.07.048 PubMedCrossRef

89.

Qiao B, Johnson NW, Gao J (2010) Epithelial-mesenchymal transition in oral squamous cell carcinoma triggered by transforming growth factor-beta 1 is snail family-dependent and correlates with matrix metalloproteinase-2 and-9 expressions. Int J Oncol 37(3):663–668PubMed

90.

Costea DE, Hills A, Osman AH, Thurlow J, Kalna G, Huang X, Pena Murillo C, Parajuli H, Suliman S, Kulasekara KK, Johannessen AC, Partridge M (2013) Identification of two distinct carcinoma-associated fibroblast subtypes with differential tumor-promoting abilities in oral squamous cell carcinoma. Cancer Res 73(13):3888–3901. https://doi.org/10.1158/0008-5472.CAN-12-4150 PubMedCrossRef

91.

Chen MF, Wang WH, Lin PY, Lee KD, Chen WC (2012) Significance of the TGF-beta I/IL-6 axis in oral cancer. Clin Sci 122(10):459–472. https://doi.org/10.1042/CS20110434 PubMedPubMedCentralCrossRef

92.

Sherr CJ (1996) Cancer cell cycles. Science 274(5293):1672–1677. https://doi.org/10.1126/science.274.5293.1672 PubMedCrossRef

93.

Hartwell LH, Kastan MB (1994) Cell cycle control and cancer. Science 266(5192):1821–1828. https://doi.org/10.1126/science.7997877 PubMedCrossRef

94.

Wong QW, Lung RW, Law PT et al (2008) MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology 135(1):257–269. https://doi.org/10.1053/j.gastro.2008.04.003 PubMedCrossRef

95.

Hengartner MO (2000) The biochemistry of apoptosis. Nature 407(6805):770–776. https://doi.org/10.1038/35037710 PubMedCrossRef

96.

Danial NN, Korsmeyer SJ (2004) Cell death: critical control points. Cell 116(2):205–219. https://doi.org/10.1016/S0092-8674(04)00046-7 PubMedCrossRef

97.

Hsu HL, Shu HB, Pan MG et al (1996) TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84(2):299–308. https://doi.org/10.1016/S0092-8674(00)80984-8 PubMedCrossRef

98.

Ando M, Kawazu M, Ueno T, Fukumura K, Yamato A, Soda M, Yamashita Y, Choi YL, Yamasoba T, Mano H (2013) Cancer-associated missense mutations of caspase-8 activate nuclear factor-kappa B signaling. Cancer Sci 104(8):1002–1008. https://doi.org/10.1111/cas.12191 PubMedCrossRef

99.

Tsai LL, CC Y, Chang YC et al (2011) Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma. J Oral Pathol Med 40(8):621–628. https://doi.org/10.1111/j.1600-0714.2011.01015.x PubMedCrossRef

100.

Min AJ, Zhu C, Peng SP et al (2015) MicroRNAs as important players and biomarkers in oral carcinogenesis. Biomed Res Int 2015:186904PubMedPubMedCentral

101.

Clague J, Lippman SM, Yang HS et al (2010) Genetic variation in MicroRNA genes and risk of oral premalignant lesions. Mol Carcinog 49(2):183–189. https://doi.org/10.1002/mc.20588 PubMedPubMedCentral

Titel: MicroRNAs as effective surrogate biomarkers for early diagnosis of oral cancer
verfasst von: Min Cao
Lijuan Zheng
Jianzhou Liu
Thomas Dobleman
Shen Hu
Vay Liang W. Go
Ge Gao
Gary Guishan Xiao
Publikationsdatum: 03.01.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Clinical Oral Investigations / Ausgabe 2/2018
Print ISSN: 1432-6981
Elektronische ISSN: 1436-3771
DOI: https://doi.org/10.1007/s00784-017-2317-6

Neu im Fachgebiet Zahnmedizin

19.04.2024 | Vorhofflimmern | Nachrichten

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

MicroRNAs as effective surrogate biomarkers for early diagnosis of oral cancer

Abstract

Background

Objective

Methods

Results

Conclusions

Neu im Fachgebiet Zahnmedizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Invasive Zahnbehandlung: Wann eine Antibiotikaprophylaxe vor infektiöser Endokarditis schützt

Zell-Organisatoren unter Druck: Mechanismen des embryonalen Zahnwachstums aufgedeckt

Die Oralprophylaxe & Kinderzahnheilkunde umbenannt

Newsletter

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Chemical composition and morphology study of bovine enamel submitted to different sterilization methods

Soft tissue profile changes after Functional Mandibular Advancer or Herbst appliance treatment in class II patients

Tooth brushing motion patterns with manual and powered toothbrushes—a randomised video observation study

Volatile organic compounds in the breath of oral candidiasis patients: a pilot study

Trigemino-gustatory interactions: a randomized controlled clinical trial assessing the effects of selective anesthesia of dental afferents on taste thresholds

Does a face-bow lead to better occlusion in complete dentures? A randomized controlled trial: part I

Neu im Fachgebiet Zahnmedizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Invasive Zahnbehandlung: Wann eine Antibiotikaprophylaxe vor infektiöser Endokarditis schützt

Zell-Organisatoren unter Druck: Mechanismen des embryonalen Zahnwachstums aufgedeckt

Die Oralprophylaxe & Kinderzahnheilkunde umbenannt

Newsletter